TWI900703B - 與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法 - Google Patents

與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法

Info

Publication number
TWI900703B
TWI900703B TW110145581A TW110145581A TWI900703B TW I900703 B TWI900703 B TW I900703B TW 110145581 A TW110145581 A TW 110145581A TW 110145581 A TW110145581 A TW 110145581A TW I900703 B TWI900703 B TW I900703B
Authority
TW
Taiwan
Prior art keywords
polypeptide
seq
polypeptide complex
amino acid
complex
Prior art date
Application number
TW110145581A
Other languages
English (en)
Chinese (zh)
Other versions
TW202237654A (zh
Inventor
大衛 坎貝爾
湯瑪斯 Ｒ 迪拉蒙多
Original Assignee
美商詹努克斯治療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商詹努克斯治療有限公司 filed Critical 美商詹努克斯治療有限公司
Publication of TW202237654A publication Critical patent/TW202237654A/zh
Application granted granted Critical
Publication of TWI900703B publication Critical patent/TWI900703B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW110145581A 2020-12-09 2021-12-07 與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法 TWI900703B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063123329P 2020-12-09 2020-12-09
US63/123,329 2020-12-09
US202163187699P 2021-05-12 2021-05-12
US63/187,699 2021-05-12

Publications (2)

Publication Number Publication Date
TW202237654A TW202237654A (zh) 2022-10-01
TWI900703B true TWI900703B (zh) 2025-10-11

Family

ID=81849994

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110145581A TWI900703B (zh) 2020-12-09 2021-12-07 與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法

Country Status (9)

Country Link
US (3) US11555078B2 (https=)
EP (1) EP4259193A4 (https=)
JP (1) JP7850721B2 (https=)
KR (1) KR20230135575A (https=)
AU (1) AU2021396172A1 (https=)
CA (1) CA3201588A1 (https=)
MX (1) MX2023006817A (https=)
TW (1) TWI900703B (https=)
WO (1) WO2022125576A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
EP4259177A4 (en) * 2020-12-08 2024-11-06 Janux Therapeutics, Inc. Peptide compositions and methods for anti-cd3 binding domains
AU2021396172A1 (en) 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
CN121426967A (zh) * 2023-02-10 2026-01-30 阿穆尼克斯制药公司 靶向前列腺特异性膜抗原（psma）的组合物及其制备和使用方法
AU2024293320A1 (en) * 2023-07-14 2026-02-05 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
TW202528349A (zh) * 2023-11-03 2025-07-16 美商詹努克斯治療有限公司 用於靶向psma及cd28之抗體及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209304A1 (en) * 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
WO2019222278A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Dual binding moiety

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031264A1 (en) 1996-01-25 2001-10-18 Andrew Segal Vaccine compositions and methods of modulating immune responses
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
SI1629011T1 (sl) 2003-05-31 2010-05-31 Micromet Ag Humane molekule za vezavo anti hu cd
BRPI0713421A2 (pt) 2006-06-14 2012-03-13 Imclone Systems Incorporated Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
ES2650224T3 (es) 2007-08-21 2018-01-17 Amgen, Inc. Proteínas de unión al antígeno C-FMS humano
TW200927761A (en) * 2007-09-26 2009-07-01 U3 Pharma Ag Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
JP6126782B2 (ja) 2008-10-01 2017-05-10 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
PL2352763T5 (pl) 2008-10-01 2023-01-30 Amgen Research (Munich) Gmbh Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
EP2820047B1 (en) 2012-03-01 2018-04-25 Amgen Research (Munich) GmbH Long life polypeptide binding molecules
CN104540518A (zh) 2012-04-27 2015-04-22 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
WO2014012085A2 (en) * 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
CN104271602B (zh) 2012-11-21 2020-08-21 武汉友芝友生物制药有限公司 双特异性抗体
CN105283201B (zh) 2013-03-14 2019-08-02 斯克利普斯研究所 靶向剂抗体偶联物及其用途
WO2014140358A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
IL270562B (en) 2014-01-31 2022-08-01 Cytomx Therapeutics Inc Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
JP7020909B2 (ja) 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
AU2015323313B2 (en) 2014-09-25 2021-04-01 Amgen Inc. Protease-activatable bispecific proteins
MX2017006016A (es) 2014-11-11 2017-06-19 Amunix Operating Inc Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
EP3778640A1 (en) 2015-05-01 2021-02-17 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
EA201792573A1 (ru) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
EP3322715B1 (en) 2015-07-14 2023-10-18 BioNTech SE Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EP3411404B1 (en) 2016-02-03 2022-11-09 Amgen Research (Munich) GmbH Psma and cd3 bispecific t cell engaging antibody constructs
KR20230041739A (ko) 2016-03-08 2023-03-24 매버릭 테라퓨틱스, 인크. 유도성 결합 단백질 및 사용 방법
HRP20230528T1 (hr) 2016-03-22 2023-08-04 F. Hoffmann - La Roche Ag Bispecifične molekule t stanica aktivirane proteazom
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
CN116987189A (zh) 2016-05-20 2023-11-03 哈普恩治疗公司 单链可变片段cd3结合蛋白质
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
MX2019004775A (es) 2016-11-03 2019-08-05 Squibb Bristol Myers Co Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos.
EP3544629A4 (en) 2016-11-23 2020-06-17 Harpoon Therapeutics, Inc. PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF
US11690919B2 (en) 2017-01-17 2023-07-04 The Texas A&M University System Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
IL302613B2 (en) 2017-09-08 2025-04-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
CA3287794A1 (en) 2017-10-14 2025-10-27 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
CN111433224B (zh) 2017-11-17 2024-03-19 南京传奇生物科技有限公司 抗pd-l1的单结构域抗体及其变体
EP3728326A4 (en) * 2017-12-21 2021-12-15 Amunix Pharmaceuticals, Inc. SEPARATING SEGMENTS AND BINDING COMPOSITIONS THEREFORE
JP2021518603A (ja) 2018-03-20 2021-08-02 シートムエックス セラピューティクス，インコーポレイテッド 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法
KR20210020903A (ko) 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
WO2020033837A1 (en) 2018-08-09 2020-02-13 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins
US20230132385A9 (en) * 2018-09-20 2023-04-27 Tikcro Technologies Ltd. Antibodies specific to ctla-4 and uses thereof
CN120463822A (zh) 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
MY205459A (en) 2018-12-06 2024-10-22 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CA3125302A1 (en) * 2019-01-18 2020-07-23 University Of Southern California Methods and compositions to improve the safety and efficacy of cellular therapies
US20220144949A1 (en) 2019-03-05 2022-05-12 Takeda Pharmaceutical Limited Company CONDITIONALLY ACTIVATED BINDING PROTEINS CONTAINING Fc REGIONS AND MOIETIES TARGETING TUMOR ANTIGENS
WO2020181140A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
EP3966250A4 (en) * 2019-05-07 2022-11-23 Immunorizon Ltd. PRECURSOR TRI-SPECIFIC ANTIBODY CONSTRUCTIONS AND METHODS OF USE THEREOF
CN114423499A (zh) 2019-06-06 2022-04-29 佳努克斯治疗公司 与肿瘤激活的t细胞衔接子相关的组合物和方法
US20230121775A1 (en) 2019-06-26 2023-04-20 Amunix Pharmaceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
WO2022035866A1 (en) 2020-08-11 2022-02-17 Janux Therapeutics, Inc. Cleavable linker compositions and methods
EP4228694A4 (en) 2020-10-15 2024-12-18 Janux Therapeutics, Inc. ANTIBODIES DIRECTED AGAINST PSMA AND CD3 AND USES THEREOF
WO2022098909A1 (en) * 2020-11-06 2022-05-12 Harpoon Therapeutics, Inc. Epcam targeting trispecific protein for treatment of cancer
EP4259177A4 (en) 2020-12-08 2024-11-06 Janux Therapeutics, Inc. Peptide compositions and methods for anti-cd3 binding domains
CN117042788A (zh) 2020-12-08 2023-11-10 佳努克斯治疗公司 半衰期延长组合物和方法
AU2021396172A1 (en) 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209304A1 (en) * 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
WO2019222278A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Dual binding moiety

Also Published As

Publication number Publication date
JP2023552812A (ja) 2023-12-19
AU2021396172A1 (en) 2023-07-06
US11555078B2 (en) 2023-01-17
CA3201588A1 (en) 2022-06-16
KR20230135575A (ko) 2023-09-25
EP4259193A4 (en) 2025-01-15
US20220177600A1 (en) 2022-06-09
JP7850721B2 (ja) 2026-04-23
WO2022125576A1 (en) 2022-06-16
TW202237654A (zh) 2022-10-01
US20230348618A1 (en) 2023-11-02
MX2023006817A (es) 2023-08-14
EP4259193A1 (en) 2023-10-18
US20260001963A1 (en) 2026-01-01

Similar Documents

Publication Publication Date Title
TWI900703B (zh) 與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法
JP7681681B2 (ja) 切断可能リンカー組成物および方法
US12161724B2 (en) Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
US20240034806A1 (en) Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
US20240034814A1 (en) Half-life extending compositions and methods
CN116981682A (zh) 用于抗-cd3结合结构域的肽组合物和方法
US20240043565A1 (en) Antibodies targeting psma and cd3 and uses thereof
CN117042792A (zh) 涉及靶向psma和效应细胞抗原的肿瘤活化抗体的组合物和方法
HK40101255A (zh) 涉及靶向psma和效应细胞抗原的肿瘤活化抗体的组合物和方法
TW202528349A (zh) 用於靶向psma及cd28之抗體及其用途
CN117042801A (zh) 涉及靶向trop2和效应细胞抗原的肿瘤活化抗体的组合物和方法